{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:31:17Z","timestamp":1773898277015,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Pharmacology Department"},{"name":"Faculty of Pharmacy"},{"name":"Suez Canal University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jpba.2019.05.069","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T06:41:16Z","timestamp":1559284876000},"page":"226-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["An LC\u2013MS\/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies"],"prefix":"10.1016","volume":"174","author":[{"given":"Mohamed Saleh","family":"Elgawish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moustafa K.","family":"Soltan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud M.","family":"Sebaiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.05.069_bib0005","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/0002-8703(91)90943-C","article-title":"Hyperlipidemia in hypertension causes and prevention","volume":"122","author":"Ames","year":"1991","journal-title":"Am. Heart J."},{"key":"10.1016\/j.jpba.2019.05.069_bib0010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-200241050-00003","article-title":"Pharmacokinetic\u2013pharmacodynamic drug interactions with HMG-CoA reductase inhibitors","volume":"41","author":"Williams","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2019.05.069_bib0015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/01.ATV.16.3.425","article-title":"Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels","volume":"3","author":"Jukema","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jpba.2019.05.069_bib0020","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s00592-005-0176-0","article-title":"Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator","volume":"42","author":"Kurtz","year":"2005","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.jpba.2019.05.069_bib0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1527-3466.2002.tb00099.x","article-title":"Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor","volume":"20","author":"Olsson","year":"2002","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.jpba.2019.05.069_bib0030","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1586\/14779072.1.4.495","article-title":"Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia","volume":"1","author":"Rosenson","year":"2003","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.jpba.2019.05.069_bib0035","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/S0149-2918(03)80316-8","article-title":"Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers","volume":"25","author":"Martin","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jpba.2019.05.069_bib0040","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2165\/00003495-200464090-00011","article-title":"Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy","volume":"64","author":"Croom","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2019.05.069_bib0045","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/00912700122010906","article-title":"The pharmacokinetics and pharmacodynamics of irbesartan in heart failure","volume":"41","author":"Kostis","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2019.05.069_bib0050","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/j.atherosclerosis.2014.05.792","article-title":"Efficacy and safety of fixed-dose combination of rosuvastatin and irbesartan in patients with dyslipidemia and hypertension","volume":"235","author":"Kim","year":"2014","journal-title":"Atheroscler."},{"key":"10.1016\/j.jpba.2019.05.069_bib0055","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1570-0232(02)00088-0","article-title":"Quantification of rosuvastatin in human plasma by automated solid phase extraction using tandem mass spectrometric detection","volume":"772","author":"Hull","year":"2002","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.jpba.2019.05.069_bib0060","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1590\/S0103-50532005000600009","article-title":"Estimation of rosuvastatin in human plasma by HPLC tandem mass spectroscopic method and its application to bioequivalence study","volume":"16","author":"Singh","year":"2005","journal-title":"J Brazilian Chem Soc."},{"key":"10.1016\/j.jpba.2019.05.069_bib0065","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jpba.2006.12.022","article-title":"Quantitative determination of rosuvastatin in human plasma by ion pair liquid\u2013liquid extraction using liquid chromatography with electrospray ionization tandem mass spectrometry","volume":"44","author":"Lan","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.05.069_bib0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jchromb.2007.05.012","article-title":"Liquid chromatography\/negative ion electrospray tandem mass spectrometry method for the quantification of rosuvastatin in human plasma: application to a pharmacokinetic study","volume":"856","author":"Gao","year":"2007","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.jpba.2019.05.069_bib0075","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00216-011-5548-4","article-title":"A simple assay for the simultaneous determination of rosuvastatin acid, rosuvastatin-5S-lactone, and N-desmethyl rosuvastatin in human plasma using liquid chromatography\u2013tandem mass spectrometry (LC\/MS\/MS)","volume":"402","author":"Macwan","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2019.05.069_bib0080","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/bmc.2944","article-title":"Development and validation of a sensitive method for simultaneous determination of rosuvastatin and N-desmethyl rosuvastatin in human plasma using liquid chromatography\/negative electrosprayionization\/tandem mass spectrometry","volume":"17","author":"Lee","year":"2013","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2019.05.069_bib0085","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/10826076.2014.982866","article-title":"Determination of Rosuvastatin and its metabolite N-Desmethyl rosuvastatin in human plasma by liquid chromatography\u2013high resolution mass spectrometry: method development, validation, and application to pharmacokinetic study","volume":"38","author":"Yasar","year":"2015","journal-title":"J. Liq. Chromatogr. Rel. Tech."},{"key":"10.1016\/j.jpba.2019.05.069_bib0090","first-page":"740","article-title":"Method development and validation of irbesartan using LCMS\/MS: application to pharmacokinetic studies","volume":"2","author":"Ganesan","year":"2010","journal-title":"J. Chem. Pharm. Res."},{"key":"10.1016\/j.jpba.2019.05.069_bib0095","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ajps.2013.11.005","article-title":"Quantitative estimation of irbesartan in two different matrices and its application to human and dog bioavailability studies using LC-MS\/MS","volume":"8","author":"Hari","year":"2013","journal-title":"Asian J Pharm Sci."},{"key":"10.1016\/j.jpba.2019.05.069_bib0100","first-page":"335","article-title":"LC-MS\/MS assay for irbesartan in human plasma using solid phase extraction technique: a pharmacokinetic study","volume":"9","author":"Mahitej","year":"2015","journal-title":"Inter J Pharm Sci."},{"key":"10.1016\/j.jpba.2019.05.069_bib0105","first-page":"206","article-title":"LC\/MS\/MS method for the simultaneous estimation of losartan potassium and irbesartan in rat plasma","volume":"1","author":"Prasad","year":"2009","journal-title":"Int J Pharm Sci."},{"key":"10.1016\/j.jpba.2019.05.069_bib0110","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpba.2009.10.023","article-title":"Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma using HPLC coupled with tandem mass spectrometry: application to bioequivalence studies","volume":"51","author":"Tutunji","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.05.069_bib0115","first-page":"749","article-title":"Comparative bioavailability of two irbesartan\/hydrochlorothiazide tablet formulations in Indonesian healthy subjects","volume":"60","author":"Sasongko","year":"2010","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.jpba.2019.05.069_bib0120","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jchromb.2014.03.002","article-title":"Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by ultra high performance liquid chromatography tandem mass spectrometry and its application to a bioequivalence study","volume":"957","author":"Qiu","year":"2014","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2019.05.069_bib0125","first-page":"257","article-title":"Bioequivalence studies for 2 different strengths of irbesartan\/hydrochlorothiazide combination in healthy volunteers: 300\/25 mg and 300\/12.5 mg film-coated tablets","volume":"64","author":"Canovas","year":"2014","journal-title":"Drug Res. (Stuttg)"},{"key":"10.1016\/j.jpba.2019.05.069_bib0130","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"An add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.jpba.2019.05.069_bib0135","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jare.2014.08.010","article-title":"Simultaneous determination of rosuvastatin and amlodipine in human plasma using tandem mass spectrometry: application to disposition kinetics","volume":"6","author":"Anjaneyulu","year":"2015","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.jpba.2019.05.069_bib0140","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jpba.2012.08.012","article-title":"Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography\/tandem mass spectrometry method and its application in pharmacokinetic study","volume":"71","author":"Chang","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.05.069_bib0145","series-title":"Guidance for Industry, Bioanalytical Method Validation","author":"U.S. Department of Health and Human Services Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.jpba.2019.05.069_bib0150","doi-asserted-by":"crossref","first-page":"311S","DOI":"10.1016\/S0895-7061(97)00391-9","article-title":"The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations","volume":"10","author":"Brunner","year":"1997","journal-title":"Amer J Hyperten."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519310167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519310167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T20:56:27Z","timestamp":1564174587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519310167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":30,"alternative-id":["S0731708519310167"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.05.069","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An LC\u2013MS\/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.05.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}